Cara Therapeutics, Inc. (NASDAQ:CARA) Receives $36.00 Consensus Price Target from Analysts
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) has earned a consensus rating of “Hold” from the five research firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating. The average 12-month price target among analysts that have covered the stock in the last […]
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) has earned a consensus rating of “Hold” from the five research firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating. The average 12-month price target among analysts that have covered the stock in the last […]
